loader2
Login Open ICICI 3-in-1 Account
Text Size
Text to Speech
Color Contrast
Pause Animations

Wockhardt Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Wockhardt Ltd. 10 Feb 2026 15:15 PM

Q3FY26 Quarterly Result Announced for Wockhardt Ltd.

Pharmaceuticals company Wockhardt announced Q3FY26 results

Financial Highlights:

  • Revenue of Rs 888 crore in Q3FY26 compared to Rs 725 crore in Q3FY25 growth of 22%.
  • EBITDA of Rs 173 crore compared to Rs 100 crore in Q3FY25, growth of 72%.
  • Profit before tax Rs 67 crore for Q3FY26 as compared to Rs 21 crore in Q3FY25.
  • Profit after tax Rs 61 crore against Rs 20 crore during Q3FY25.

Business Highlights:

  • India Branded Business stood at Rs 146 crore in Q3FY26 with a growth of 28% compared to the previous year. The India Business growth was aided by a substantial jump in our branded operations due to performance driven by the Diabetic therapy, NCE (EMROK), and the introduction of the Regenerative Derma segment.
  • UK region stood at Rs 343 crore in Q3FY26 with a growth of 15% compared to the previous year.
  • Emerging Markets region stood at Rs 264 crore in Q3FY26 with a growth of 48% compared to the previous year. The robust growth was driven mainly from our Biotech Insulin segment. The Latam operations contributed significant traction to the segment growth.
  • Irish region stood at Rs 57 crore in Q3FY26 with a growth of 23% compared to the previous year.
  • The overall Biotech operations for the quarter stood at Rs 213 crore, recording a growth of 96% vs Q4FY25 and 38% vs Q2FY26. This robust achievement is fuelled by our Emerging Market biotech segment growing at > 50 % with accelerated business opportunities and strategic business partnerships, new deal acquisitions from our key markets like Thailand, Egypt, Algeria and LATAM. Our Domestic Biotech operations continues to grow at double digit pace and is poised for decent growth in the future.

Result PDF

Pharmaceuticals company Wockhardt announced Q2FY26 results

  • Revenue for Q2FY26 is Rs 782 crore compared to Rs 738 crore in the previous quarter. QoQ growth of 58% in EBITDA in Q2FY26, EBITDA for Q2FY26 of Rs 160 crore compared to Rs 101 crore in the earlier quarter
  • EBITDA: Rs 160 crore compared to Rs 101 crore in the previous quarter.
  • EBITDA Margin: 20.5% for Q2FY26.
  • Profit before tax: Rs 91 crore for Q2FY26 as compared to loss of Rs -109 crore in the previous quarter.
  • Profit after tax: Rs 82 crore compared to Rs -108 crore in the previous quarter.

Result PDF

Pharmaceuticals company Wockhardt announced Q1FY26 results

  • Revenue for Q1FY26 is Rs 738 crore compared to Rs 747 crore in Q1FY25.
  • EBITDA for Q1FY26 of Rs 101 crore compared to Rs 100 crore in Q1FY25.
  • EBITDA Margin: 13.7% for Q1FY26.
  • PBT: Rs -109 crore compared to Rs -6 crore during Q1FY25.
  • PAT: Rs -108 crore compared to Rs -16 crore during Q1FY25.
  • PAT Margin: -14.6% for Q1FY26.

Result PDF

Pharmaceuticals company Wockhardt announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • Revenue for Q4FY25 of Rs 743 crore compared to Rs 750 crore in the previous year.
  • QoQ growth of 13% in EBITDA in Q4FY25, EBITDA for Q4FY25 of Rs 79 crore compared to Rs 70 crore in the previous year.

FY25 Financial Highlights:

  • Revenue for FY25 of Rs 3,033 crore compared to Rs 2,879 crore in the previous year.
  • YoY growth of 67% in EBITDA in FY25, EBITDA for FY25 of Rs 418 crore compared to Rs 251 crore in the previous year.

Result PDF

Pharmaceuticals company Wockhardt announced H1FY25 & Q2FY25 results

Q2FY25 Financial Highlights:

  • QoQ growth of 7% in revenue in Q2FY25, Revenue for Q2FY25 of Rs 818 crore compared to Rs 762 crore in the Q2FY24.
  • QoQ growth of 71% in EBITDA in Q2FY25, EBITDA for Q2FY25 of Rs 139 crore compared to Rs 81 crore in the Q2FY24.

H1FY25 Financial Highlights:

  • YoY growth of 10% in revenue in H1FY25, Revenue for H1FY25 of Rs 1,565 crore compared to Rs 1,420 crore in the H1FY24.
  • YoY growth of 112% in EBITDA in H1FY25, EBITDA for H1FY25 of Rs 239 crore compared to Rs 113 crore in the H1FY24.

Result PDF

Pharmaceuticals company Wockhardt announced Q4FY24 & FY24 results:

  • YoY growth of 7% in revenue in FY24, Revenue for FY24 of Rs 2,879 crore compared to Rs 2,693 crore in the previous year. QoQ growth of 6%, Revenue for the quarter being Rs 750 crore compared to Rs 710 crore in Q4FY23.
  • YoY growth of 74% in EBITDA in FY24, EBITDA for FY24 at Rs 251 crore compared to Rs 144 crore in the previous year. Quarterly growth in EBITDA by 49% compared to the previous year, EBITDA for Q4FY24 at Rs 70 crore compared to Rs 47 crore in Q4FY23.
  • UK Business stood at Rs 268 crore in Q4FY24 compared to Rs 242 crore in Q4FY23 registering a growth of 11% and contributed about 36% of Global Revenue in the current quarter. UK Business stood at Rs 1,041 crore in FY24 compared to Rs 887 crore in FY23 registering a growth of 17% and contributed about 36% of Global Revenue in FY24.
  • Emerging Markets Business of the Company stood at Rs 190 crore in Q4FY24 contributing to about 25% of the Global Revenue. Emerging Markets Business stood at Rs 642 crore in FY24 compared to Rs 555 crore in FY23 registering a growth of 16% and contributing to about 22% of the Global Revenue.
  • Irish Business stood at Rs 45 crore in Q4FY24 compared to Rs 44 crore in Q4FY23 registering a growth of 4%. Irish Business stood at Rs 179 crore in FY24 compared to Rs 158 crore in FY23 registering a growth of 13%.
  • India Business stood at Rs 181 crore in Q4FY24 compared to Rs 125 crore in the previous year registering a growth of 45%. India business stood at Rs 641 crore compared to Rs 609 crore in FY23 registering a growth of 5% and contributing to 22% of the Global Revenue in FY24.
  • US Business stood at Rs 42 crore in Q4FY24 contributing 6% of the Global Revenue. US Business stood at Rs 175 crore in FY24 contributing 6% of the Global Revenue.

Result PDF

Pharmaceuticals company Wockhardt announced Q1FY24 results:

  • Revenue of Rs 658 crore in Q1FY24 compared to Rs 596 crore in Q1FY23 registering a growth of 10%.
  • EBITDA for Q1FY24 is Rs 32 crore as compared to Rs (15) crore in Q4FY23 registering a 3-fold growth.
  • 11 patents were filed during Q1FY24 and the cumulative filings to date are 3,250. The company was granted 12 patents during Q1FY24 and now holds 822 patents.
  • R&D expenses remained constant at Rs 36 crore in Q1FY24 compared to Q1FY23.
  • Profit After Tax of Rs (136) crore in Q1FY24 compared to Rs (75) crore in Q1FY23.

 

 

Result PDF

Pharmaceuticals company Wockhardt announced Q4FY23 & FY23 results:

  • Q4FY23:
    • The Company recorded a Revenue of Rs 710 crore in Q4FY23 vs Rs 666 crore in Q4FY22, up 7%
    • EBITDA for Q4FY23 is Rs 47 crore as compared to Rs (22) crore in Q4FY22 registering a substantial growth of 314%
    • UK Business stood at Rs 242 crore in Q4FY23 compared to Rs 223 crore in Q3FY23 registering a growth of 8%. UK Business contributed about 36% of Global Revenue.
    • India Business stood at Rs 125 crore in Q4FY23. India's Business contributed 19% of the Global Revenue.
    • Emerging Markets Business of the Company stood at Rs 173 crore in Q4FY23 compared to Rs 148 crore in Q3FY23 registering a growth of 16%. Emerging Markets Business contributed about 25% of the Global Revenue.
    • Irish Business stood at Rs 44 crore in Q4FY23 compared to Rs 40 crore in Q3FY23 showing a growth of 10%.
    • US Business stood at Rs 50 crore in Q4FY23. US Business contributed 7% of the Global Revenue.
  • FY23:
    • UK Business stood at Rs 887 crore in FY23. UK Business contributed about 33% of Global Revenue.
    • India's Business stood at Rs 609 crore in FY23. India's Business contributed 23% of the Global Revenue.
    • Emerging Markets Business of the Company stood at Rs 555 crore in FY23. Emerging Markets Business contributed about 21% of the Global Revenue.
    • Irish Business stood at Rs 158 crore in FY23 compared to Rs 153 crore in FY22, up 4% 
    • US Business stood at Rs 303 crore in FY23. US Business contributed 11% of the Global Revenue.

 

 

Result PDF

Pharmaceuticals firm Wockhardt announced Q3FY23 results:

Q3FY23:

  • UK business stood at Rs 223 crore in Q3FY23. UK business contributed about 32% of global revenue.
  • India Business stood at Rs 175 crore compared to Rs 158 crore in Q3FY22, registering a growth of 11%. India Business contributed 25% of the global revenue.
  • Emerging markets business of the company stood at Rs 148 crore in Q3FY23 compared to Rs 117 crore in Q2FY23, registering a growth of 27%. Emerging markets business contributed about 21% of the global revenue.
  • Irish business stood at Rs 40 crore in Q3FY23 compared to Rs 38 crore in Q2FY23, showing a growth of 4%.
  • US business stood at Rs 91 crore in Q3FY23. US business contributed 13% of the global revenue.
  • Research and development expenditure during the quarter was at Rs 40 crore (6% to sales) and including capital expenditure was at 10.3% to sales.

9MFY23:

  • UK business stood at Rs 645 crore in 9MFY23. UK business contributed about 33% of global revenue.
  • India business stood at Rs 483 crore. India business contributed 25% of the global revenue.
  •  Emerging markets business of the company stood at Rs 382 crore in 9MFY23. Emerging markets business contributed about 19% of the global revenue.
  • Irish business stood at Rs 115 crore in 9MFY23.
  • US business stood at Rs 253 crore in 9MFY23. US business contributed 13% of the global revenue.
  • Research and development expenditure during the period was at Rs 115 crore (6% to sales) and including capital expenditure was at 10.9% to sales.

Result PDF

Pharmaceutical company Wockhardt announced Q2FY23 results:

  • The Company recorded a Revenue of Rs.679 crore in Q2FY23 compared to Rs.595 crore in the previous quarter registering a growth of 14%.
  • EBITDA for the quarter is Rs.43 crore as compared to Rs. (16) crore in Q1FY23 registering a substantial growth of 369%.
  • Q2FY23 Global revenue:
    • UK Business stood at Rs.226 crore in Q2FY23 (PY Rs.387 Cr). UK Business contributed about 33% of Global Revenue.
    • India Business: India Business stood at Rs.150 crore (PY Rs.187 crore). India's Business contributed 22% of the Global Revenue. EMROK, the NCE launched during FY21 continues to provide unmatched benefits to patients.
    • The emerging Markets Business of the Company stood at Rs.117 crore in Q2FY23 (PY Rs.165 Cr). Emerging Markets Business contributed about 17% of the Global Revenue.
    • Irish Business stood flat at Rs.38 crore in Q2FY23 compared to the previous year.
    • US Business stood at Rs.89 crore in Q2FY23 compared to Rs.61 crore in the previous year registering a growth of 45%. US Business contributed 13% of the Global Revenue. US business was impacted by price erosion and supply disruptions.
  • Research and Development expenditure during the quarter was at Rs.39 crore (6% to sales) and including capital expenditure was at 11.8% to sales.

 

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Get it on google Play Store Download on the App Store
market app